Knowledge Center

This year’s Scope Summit once again brought thousands in the clinical research space together, offering a glimpse into the evolving operational and technological landscapes shaping the future of trials.  

‍

The J.P. Morgan Healthcare Conference returned to San Francisco this year, bringing significant deals and strategic shifts that signal where healthcare is headed. While this year’s weather outside was dry and sunny, a substantial change from the prior two years' rainy conferences, the conditions inside differed, with several companies making waves. 

‍

In November, we released an update to Medable Studio titled Medable AI. This latest update furthers Studio's unique value proposition, offering sponsors and CROs unprecedented control over the study creation and launch process, as well as scalability, speed, and streamlining of operations.  This provides the easiest, fastest path to study launch in the industry to date.

If this already sounds like something you could use, check out a demo or an in-depth look at its feature set here. 

For everyone else, read below to discover what exactly Medable AI has to offer.

‍

A top-10 global pharmaceutical company aimed to address eCOA adherence and patient enrollment challenges faced by clinical trial sites and participants in Japan.

Recognizing Japan’s distinct regulatory, cultural, and logistical landscape, the company partnered with Medable todevelop an initiative to enhance the region’s patient and site experience.

‍

A top-10 pharmaceutical company was looking to reduce the amount of administrative burden on their clinical trial sites and themselves.  The sponsor sought to find a vendor that could use one eConsent system to manage paper and electronic consent.  Additionally, they sought to use the central eConsent system to populate the clinical trial sites’ IRB and EDC systems,  as well as some internal systems.

‍

A top-10 pharmaceutical company was looking to standardize the conduct of their diabetic polyneuropathy trials for future use.

Specifically, the client was looking to digitize their paper “body map” forms. These are used by participants to indicate the severity of pain on their bodies. 

Traditionally administered on paper, body map assessments had been a source of potential inefficiencies and errors. 

The client’s goal was to co-create and own their body maps, while simplifying and streamlining the process for future trials.

‍

Deployment of remote and virtual clinical trial methods and technologies, referred to collectively as decentralized clinical trials (DCTs), represents a profound shift in clinical trial practice. To our knowledge, a comprehensive assessment of the financial net benefits of DCTs has not been conducted

Research looking at mobile apps and how they may provide a meaningful access point for all stakeholders for symptom management.

From improved patient engagement to streamlined workflows, eCOA is revolutionizing clinical trials. Discover the benefits, challenges, and how sites can overcome hurdles to unlock the full potential of this technology.

Discover how advanced eCOA platforms improve patient adherence, ensuring reliable data and faster trial completion. Explore real-world successes, including adherence rates exceeding 90% in diabetes and oncology studies, powered by Medable’s eCOA (electronic clinical outcomes assessment) solutions.

Discover the transformative role of eCOA (electronic clinical outcomes assessment) vendors in modern clinical trials. From seamless integration and AI-driven analytics to patient-centric design, learn how leading platforms like Medable’s eCOA+ enhance efficiency, compliance, and data quality.

‍